IMRX
Immuneering Corp
NASDAQ · Healthcare · Biotechnology · US
$4.48
+0.45%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-30.0%
Return on equity
-28.3%
Return on assets
-32.7%
Return on invested capital
0.00x
Asset turnover
-$56.8M
Cash from operations
$2.32
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026